Pfizer is launching the first clinical trials for its PD-1xVEGF drug, while Akeso detailed the first overall survival win for ...

Eli Lilly stock soars on obesity drug success. See here to know why LLY remains a top pick with strong growth prospects and a ...

Toni Braxton's 'He Wasn't Man Enough' has new life as Lifetime movie ...

But these eye-popping innovations have an effect only if they can make their way to the patients who need them. That reality ...

Experience a 20-day survival challenge in the rainforest of Vietnam, where primitive skills and natural resources are ...

Though it will likely be a while before the project actually begins to take shape, Predator: Badlands director Dan Trachtenberg believes we will see a new Alien Vs. Predator movie at some ...

The phase 2 ChonDRAgon study compared ozekibart to placebo in patients with metastatic or unresectable conventional chondrosarcoma who been diagnosed with radiographic progression.

This encouraging oncology development arrives at a pivotal moment for Eli Lilly's primary revenue drivers. On November 17, 2025, its main competitor, Novo Nordisk, announced price reductions for its ...

The EMA’s recommendation follows evidence that the targeted therapy improves progression-free survival in patients whose ...

To read last Friday’s edition of Five things for pharma marketers to know, click here.

Overture Life SLU secured CE mark certification for its Davitri system that automates the vitrification and thawing of oocytes and embryos, making the processes more efficient, consistent and ...

Roche claimed the results make its drug giredestrant the first of its kind, a so-called oral SERD, to show a benefit in the ...